Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Viridian Therapeutics Inc's Business Segments
Viridian Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Viridian Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - Q1 FY2026
- Collaboration95.7%
- License4.3%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration | $ 0 | 95.7% |
| License | $ 0 | 4.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Viridian Therapeutics Inc
Viridian Therapeutics Inc is a biotechnology company based in the United States that is focused on developing innovative gene therapies to treat various genetic disorders. The company combines cutting-edge gene therapy technologies with a deep understanding of human genetics to create transformative treatments for patients with unmet medical needs.
Viridian Therapeutics was founded by a team of experienced scientists and entrepreneurs who have a strong background in genetics and molecular biology. They are dedicated to revolutionizing the field of gene therapy by developing targeted, safe, and effective treatments that have the potential to change the lives of patients suffering from genetic diseases.
The company's approach to gene therapy is based on using viral vectors to deliver therapeutic genetic material into target cells of the body. By utilizing the natural ability of viruses to infect cells and introduce their DNA, Viridian Therapeutics is able to deliver therapeutic genes directly to the affected cells, enabling the production of functional proteins that can correct the underlying genetic defect.
One of the key advantages of Viridian Therapeutics' approach is its focus on precision medicine. The company utilizes advanced genetic diagnostics and personalized medicine technologies to identify specific gene mutations responsible for a particular genetic disorder. This allows them to develop tailored gene therapy treatments that are designed to address the specific genetic defect in each patient. By tailoring treatments to the individual, Viridian Therapeutics aims to optimize efficacy and minimize side effects.
Viridian Therapeutics has a robust pipeline of gene therapy programs targeting a range of genetic disorders, including rare inherited diseases, neurodegenerative disorders, and certain types of cancer. The company's lead program is focused on developing a gene therapy for a rare genetic disorder that affects muscle strength and function. This debilitating disease currently has no cure and leads to progressive muscle weakness.
In addition to its therapeutic programs, Viridian Therapeutics also conducts extensive research and development activities to continually improve its gene therapy technologies. The company invests in state-of-the-art facilities and collaborates with leading academic institutions and research organizations to stay at the forefront of gene therapy advancements.
Overall, Viridian Therapeutics Inc is a biotechnology company dedicated to developing gene therapies that have the potential to transform the lives of patients with genetic disorders. Through its innovative approach, precision medicine focus, and extensive research efforts, Viridian Therapeutics is striving to make significant contributions to the field of gene therapy and bring hope to patients in need.
Viridian Therapeutics was founded by a team of experienced scientists and entrepreneurs who have a strong background in genetics and molecular biology. They are dedicated to revolutionizing the field of gene therapy by developing targeted, safe, and effective treatments that have the potential to change the lives of patients suffering from genetic diseases.
The company's approach to gene therapy is based on using viral vectors to deliver therapeutic genetic material into target cells of the body. By utilizing the natural ability of viruses to infect cells and introduce their DNA, Viridian Therapeutics is able to deliver therapeutic genes directly to the affected cells, enabling the production of functional proteins that can correct the underlying genetic defect.
One of the key advantages of Viridian Therapeutics' approach is its focus on precision medicine. The company utilizes advanced genetic diagnostics and personalized medicine technologies to identify specific gene mutations responsible for a particular genetic disorder. This allows them to develop tailored gene therapy treatments that are designed to address the specific genetic defect in each patient. By tailoring treatments to the individual, Viridian Therapeutics aims to optimize efficacy and minimize side effects.
Viridian Therapeutics has a robust pipeline of gene therapy programs targeting a range of genetic disorders, including rare inherited diseases, neurodegenerative disorders, and certain types of cancer. The company's lead program is focused on developing a gene therapy for a rare genetic disorder that affects muscle strength and function. This debilitating disease currently has no cure and leads to progressive muscle weakness.
In addition to its therapeutic programs, Viridian Therapeutics also conducts extensive research and development activities to continually improve its gene therapy technologies. The company invests in state-of-the-art facilities and collaborates with leading academic institutions and research organizations to stay at the forefront of gene therapy advancements.
Overall, Viridian Therapeutics Inc is a biotechnology company dedicated to developing gene therapies that have the potential to transform the lives of patients with genetic disorders. Through its innovative approach, precision medicine focus, and extensive research efforts, Viridian Therapeutics is striving to make significant contributions to the field of gene therapy and bring hope to patients in need.
Viridian Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for serious diseases. The company primarily operates in the field of rare diseases and conditions associated with significant unmet medical needs.
Segments
1. Therapeutic Areas:
- Rare Diseases: Viridian is geared towards addressing various rare diseases, particularly those with insufficient treatment options.
- Chronic Conditions: Engaging in research and development for chronic conditions that impact patients quality of life.
2. Research and Development:
- Focuses on advancing late-stage clinical trials to bring new therapies to market.
- Engages in preclinical studies to discover new therapeutic candidates.
3. Partnerships and Collaborations:
- Collaborates with other biotech firms, academic institutions, and research organizations to leverage expertise and resources in drug discovery and development.
Products
Viridian Therapeutics may develop a range of products aimed at addressing various medical conditions. While specific products may vary over time based on the company’s research focus and developmental progress, they generally include:
1. Therapeutic Candidates:
- Drug candidates that are in various phases of development (preclinical, Phase I, Phase II, Phase III) targeting specific disease indications.
- These candidates might be undergoing clinical trials to establish their safety and efficacy for approval.
2. Biologics:
- Potentially developing biologic therapies, which can include monoclonal antibodies, gene therapies, or other biologic products for treating rare diseases.
3. Orphan Drugs:
- Focusing on orphan drug designation for therapies aimed at rare diseases, which provides certain advantages such as tax credits and market exclusivity under regulatory frameworks.
Services
In addition to their product offerings, Viridian Therapeutics may provide a variety of services that support their research, development, and commercial efforts:
1. Clinical Trial Management:
- Planning and executing clinical trials to ensure adherence to regulatory guidelines while aiming to generate robust clinical data.
2. Regulatory Affairs:
- Providing expertise in navigating the regulatory landscape, including interactions with entities such as the FDA and EMA to secure approvals for clinical trials and marketing.
3. Patient Support Programs:
- Developing programs to support patients throughout their treatment journey, which may include education, access to therapies, and adherence programs.
4. Scientific Collaboration:
- Engaging in scientific collaborations and partnerships with other organizations, government entities, and academic institutions to enhance research capabilities and drive innovation.
Key Initiatives
Viridian is likely to focus on initiatives aimed at expanding their portfolio through strategic acquisitions, research collaborations, and innovative drug development methodologies.
In summary, Viridian Therapeutics, Inc. operates primarily in the development of cutting-edge therapeutics for rare diseases, with a comprehensive approach that encompasses various segments including R&D, clinical management, and patient support, alongside a focus on advanced biological products tailored for specific medical needs.
Segments
1. Therapeutic Areas:
- Rare Diseases: Viridian is geared towards addressing various rare diseases, particularly those with insufficient treatment options.
- Chronic Conditions: Engaging in research and development for chronic conditions that impact patients quality of life.
2. Research and Development:
- Focuses on advancing late-stage clinical trials to bring new therapies to market.
- Engages in preclinical studies to discover new therapeutic candidates.
3. Partnerships and Collaborations:
- Collaborates with other biotech firms, academic institutions, and research organizations to leverage expertise and resources in drug discovery and development.
Products
Viridian Therapeutics may develop a range of products aimed at addressing various medical conditions. While specific products may vary over time based on the company’s research focus and developmental progress, they generally include:
1. Therapeutic Candidates:
- Drug candidates that are in various phases of development (preclinical, Phase I, Phase II, Phase III) targeting specific disease indications.
- These candidates might be undergoing clinical trials to establish their safety and efficacy for approval.
2. Biologics:
- Potentially developing biologic therapies, which can include monoclonal antibodies, gene therapies, or other biologic products for treating rare diseases.
3. Orphan Drugs:
- Focusing on orphan drug designation for therapies aimed at rare diseases, which provides certain advantages such as tax credits and market exclusivity under regulatory frameworks.
Services
In addition to their product offerings, Viridian Therapeutics may provide a variety of services that support their research, development, and commercial efforts:
1. Clinical Trial Management:
- Planning and executing clinical trials to ensure adherence to regulatory guidelines while aiming to generate robust clinical data.
2. Regulatory Affairs:
- Providing expertise in navigating the regulatory landscape, including interactions with entities such as the FDA and EMA to secure approvals for clinical trials and marketing.
3. Patient Support Programs:
- Developing programs to support patients throughout their treatment journey, which may include education, access to therapies, and adherence programs.
4. Scientific Collaboration:
- Engaging in scientific collaborations and partnerships with other organizations, government entities, and academic institutions to enhance research capabilities and drive innovation.
Key Initiatives
Viridian is likely to focus on initiatives aimed at expanding their portfolio through strategic acquisitions, research collaborations, and innovative drug development methodologies.
In summary, Viridian Therapeutics, Inc. operates primarily in the development of cutting-edge therapeutics for rare diseases, with a comprehensive approach that encompasses various segments including R&D, clinical management, and patient support, alongside a focus on advanced biological products tailored for specific medical needs.